Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a clinical-stage biotechnology company that regularly reports on progress in its programs for severe autoimmune and inflammatory diseases. News about Dianthus often centers on clinical trial milestones, data readouts, licensing transactions, and capital markets activity related to its investigational therapies.
The company’s updates frequently highlight developments for claseprubart (DNTH103), an investigational monoclonal antibody targeting the classical complement pathway via active C1s inhibition, and DNTH212, an investigational bifunctional fusion protein targeting BDCA2 and BAFF/APRIL. Press releases describe Phase 2 and Phase 3 studies in neuromuscular indications such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, as well as early-stage work in systemic lupus erythematosus through a Phase 1 trial of DNTH212.
Investors and followers of DNTH news can expect coverage of clinical data presentations at medical meetings, initiation and progress of Phase 1, Phase 2, and Phase 3 trials, and regulatory milestones such as investigational new drug clearances. Company communications also include announcements of public offerings of common stock and pre-funded warrants, license and collaboration agreements with partners like Nanjing Leads Biolabs, and participation in healthcare and investor conferences.
This news feed aggregates these disclosures so readers can track how Dianthus advances its investigational complement and immune pathway therapies, how its pipeline evolves, and how financing and partnerships support ongoing development. For those monitoring DNTH, recurring themes include neuromuscular disease programs, complement biology, bifunctional immune modulation, and the company’s positioning as a clinical-stage biotech focused on severe autoimmune conditions.
Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotech company, has announced the pricing of its upsized public offering at $33.00 per share. The offering consists of 6,487,879 shares of common stock and pre-funded warrants to purchase up to 1,112,121 shares at $32.999 per warrant.
The offering is expected to generate approximately $251 million in gross proceeds before expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,140,000 shares. The proceeds will support Dianthus's preclinical and clinical development activities, working capital, and general corporate purposes. The offering is expected to close on September 11, 2025.
Dianthus Therapeutics (NASDAQ:DNTH), a clinical-stage biotech company focused on antibody complement therapeutics, has announced a proposed $150 million underwritten public offering of common stock and pre-funded warrants. The company will grant underwriters a 30-day option to purchase up to an additional $22.5 million of common stock.
The offering, led by joint book-running managers Jefferies, TD Cowen, Evercore ISI, and Stifel, will be conducted through a shelf registration statement effective since October 2024. Proceeds will support Dianthus's preclinical and clinical development activities, working capital, and general corporate purposes.
Dianthus Therapeutics (NASDAQ:DNTH) reported positive Phase 2 MaGic trial results for claseprubart (DNTH103) in treating generalized Myasthenia Gravis (gMG). Both 300mg and 600mg doses administered every two weeks showed statistically significant improvements in key efficacy measures.
The trial demonstrated rapid and sustained effectiveness starting from Week 1, with significant improvements in MG-ADL and QMG scores through Week 13. The 300mg dose proved equally effective as 600mg, supporting a convenient single-dose administration via subcutaneous autoinjector every two weeks.
Importantly, claseprubart showed a favorable safety profile with no serious infections, autoimmune symptoms, or drug-related serious adverse events. The company plans to initiate a Phase 3 gMG trial in 2026.
Dianthus Therapeutics (Nasdaq: DNTH) has scheduled a conference call and webcast for September 8, 2025 at 8:00 a.m. EDT to discuss results from their Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG).
The clinical-stage biotechnology company, focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, will host the event with a Q&A session for registered participants. Investors can access the webcast through the company's website, with a replay available afterward.
Dianthus Therapeutics (NASDAQ:DNTH) reported Q2 2025 financial results and business updates, highlighting significant progress in its clinical programs. The company's lead drug candidate claseprubart (DNTH103) is advancing in multiple trials:
The Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) completed enrollment with 65 patients, with top-line results expected in September 2025. The Phase 3 CAPTIVATE trial in CIDP and Phase 2 MoMeNtum trial in MMN are progressing with results anticipated in 2H'26.
Financially, Dianthus reported $309.1 million in cash, providing runway into 2H'27. Q2 net loss was $31.6 million ($0.88 per share), with R&D expenses of $26.3 million and G&A expenses of $8.9 million.
Dianthus Therapeutics (NASDAQ: DNTH), a clinical-stage biotech company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Marino Garcia will lead a fireside chat on June 5, 2025, at 9:55 a.m. EDT in New York City. The presentation will be accessible via webcast in the Investors section of the company's website under "News and Events". Additionally, the company's management will be available for one-on-one meetings with investors during the conference.
Dianthus Therapeutics (NASDAQ: DNTH) has appointed Simon Read, Ph.D. to its Board of Directors, while announcing Lonnie Moulder's transition from the Board. Dr. Read brings over 30 years of biopharmaceutical experience, most recently serving as CEO and founder of Mariana Oncology until its Novartis acquisition in 2024, and previously as CSO of Ra Pharma until its UCB acquisition in 2020.
Dr. Read's extensive background includes R&D leadership roles at major pharmaceutical companies and involvement in developing prominent immunology drugs like Rituxan® and Actemra®. He is currently Chairman of Ethyreal Bio's Board and a Fellow of the Royal Society of Medicine (UK). The company is advancing DNTH103 through clinical trials, with Phase 2 MaGic results expected in September.
Dianthus Therapeutics (DNTH) has completed enrollment for its Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG), exceeding the target with 65 patients enrolled. Top-line results are expected in September 2025. DNTH103 is a monoclonal antibody targeting the classical pathway by inhibiting the active C1s protein, designed for convenient self-administered subcutaneous injection every two weeks.
The trial focuses on patients with acetylcholine receptor antibody-positive gMG, with primary endpoints evaluating safety and tolerability. The U.S. gMG market exceeds 100,000 patients, with 85% having AChR autoantibody-driven disease. DNTH103 is also being evaluated in Phase 3 CAPTIVATE trial for CIDP and Phase 2 MoMeNtum trial for MMN, with results expected in 2H'26.
Dianthus Therapeutics, a clinical-stage biotech company focused on developing antibody complement therapeutics for autoimmune diseases, has announced its participation in two major investor events.
The company will be featured at:
- Baird Biotech Discovery Series - CEO Marino Garcia will join a fireside chat on May 6, 2025, at 1:30 p.m. EDT
- Bank of America 2025 Health Care Conference - Garcia will present a corporate overview on May 14, 2025, at 5:35 p.m. EDT and conduct one-on-one investor meetings
Both presentations will be accessible via webcast through the "News and Events" section of Dianthus Therapeutics' investor website.
FAQ
What is the current stock price of Dianthus Therapeutics (DNTH)?
What is the market cap of Dianthus Therapeutics (DNTH)?
